All these modulations suggest that the inhibition of HDAC6 via ITF3756 may provide a significant advantage as a cancer therapeutic approach by reducing the immunosuppressive effects of immune checkpoint molecules of myeloid cells while minimizing the toxicity typically associated with antibody-based therapies. Here, HDAC6 is linked to cancer.